Diapin Therapeutics LLC is a preclinical stage company committed to develop new antiplatelet agents for the treatment of acute coronary syndrome associated with diabetes patients. Patients with diabetes exhibit platelet hyper-reactivity and are at increased risks of adverse cardiovascular events. Clopidogrel is the most broadly used P2Y12 inhibitor to prevent arterial thrombosis. However clopidogrel has manifested clinical limitations of interindividual variability, delayed onset of action, and drug-drug interactions. These limitations are exacerbated in diabetes patients leading to elevated risks of ischemic complications. Although newer P2Y12 inhibitors such as prasugrel and ticagrelor have been shown to have better platelet inhibition, the risk of bleeding of these inhibitors is still significantly higher than that of clopidogrel therapy. Due to the epidemic growth of diabetes in the United States, the number of diabetes patients receiving antiplatelet therapy is projected to increase significantly in the next decade. Therefore there is a critical need to develop antiplatelet agents with improved benefit/risk ratio for diabetes patients. We have licensed exclusively an intellectual property from University of Michigan to develop ClopNPT, a novel conjugate of clopidogrel. Preliminary studies in animal models have shown that 1) ClopNPT rapidly (
Public Health Relevance Statement: Project Narrative Coronary heart disease is one of the leading causes of death in the United States. There is a growing demand for more efficacious and safer antiplatelet agents to prevent thrombosis in patients with acute coronary syndromes. The proposed study is expected to accelerate the development of novel antiplatelet agents that will improve survival and prognosis of diabetes patients with acute coronary syndromes.
Project Terms: acute coronary syndrome; Animal Model; Antiplatelet Drugs; Aspirin; base; Bleeding time procedure; Blood Platelets; Blood Vessels; cardiovascular risk factor; Cardiovascular system; Cause of Death; Clinical; clinical risk; clopidogrel; commercial application; comparative efficacy; Coronary heart disease; cost effective; Data; Development; Diabetes Mellitus; diabetic patient; Dose; Drug Interactions; Effectiveness; Enzymes; Epidemic; Event; Exhibits; ferric chloride; Future; Glutathione; Goals; Growth; Health; Hemorrhage; Human; improved; inhibitor/antagonist; Injury; innovation; Intellectual Property; Investigational Drugs; Investigational New Drug Application; Medical; Michigan; Modeling; novel; Oryctolagus cuniculus; outcome forecast; Patient risk; Patients; Pharmaceutical Preparations; Pharmacologic Substance; Phase; phase 1 study; pre-clinical; preclinical development; preclinical study; prevent; Prevention; Property; Resistance; Risk; risk benefit ratio; Rodent; Safety; Small Business Innovation Research Grant; Technology; Therapeutic; Therapeutic Intervention; Thrombosis; Thrombus; Time; Tongue; United States; Universities; Work
